ATE389417T1 - Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen - Google Patents

Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen

Info

Publication number
ATE389417T1
ATE389417T1 AT98912149T AT98912149T ATE389417T1 AT E389417 T1 ATE389417 T1 AT E389417T1 AT 98912149 T AT98912149 T AT 98912149T AT 98912149 T AT98912149 T AT 98912149T AT E389417 T1 ATE389417 T1 AT E389417T1
Authority
AT
Austria
Prior art keywords
compositions
methods
inflammatory bowel
bowel disease
treating inflammatory
Prior art date
Application number
AT98912149T
Other languages
German (de)
English (en)
Inventor
Thomas Julius Borody
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Application granted granted Critical
Publication of ATE389417T1 publication Critical patent/ATE389417T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98912149T 1997-04-01 1998-04-01 Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen ATE389417T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE389417T1 true ATE389417T1 (de) 2008-04-15

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912149T ATE389417T1 (de) 1997-04-01 1998-04-01 Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
EP1150666B1 (en) * 1999-02-12 2009-10-28 Washington University Gm-csf for the treatment of crohn's disease
DE60017180T2 (de) 1999-10-08 2005-12-08 Affinium Pharmaceuticals, Inc., Toronto Fab i inhibitoren
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
IL151888A0 (en) * 2000-03-28 2003-04-10 Biochemie Gmbh Granulated particles with masked taste
ES2333337T3 (es) 2000-08-29 2010-02-19 Biocon Limited Uso de una composicion farmaceutica que contiene un derivado de acido para-aminofenilacetico para tratar afecciones inflamatorias del tracto gastrointestinal.
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
AU2003298937A1 (en) * 2002-12-06 2004-06-30 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
CA2553775A1 (en) * 2004-01-20 2005-08-11 Richard F. Harty Compositions and methods of treatment for inflammatory diseases
AU2005209948B2 (en) 2004-02-06 2009-09-10 Pharmatel (R&D) Pty Limited Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
EP3391882A1 (en) * 2008-02-08 2018-10-24 Red Hill Biopharma Ltd. Compositions comprising rifabutin, clarithromycin, and clofazimine
CA2721981A1 (en) * 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
US20110082120A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
CA2778181C (en) 2009-10-26 2024-05-28 Thomas Julius Borody Therapy for enteric infections
WO2011137103A1 (en) 2010-04-26 2011-11-03 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
CA2821196C (en) 2010-12-13 2022-11-22 Thomas Julius Borody Gastric and colonic formulations and methods for making and using them
TWI573590B (zh) 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
DK2861608T3 (da) 2012-06-19 2019-06-24 Debiopharm Int Sa Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
ES2717282T3 (es) 2012-07-27 2019-06-20 Redhill Biopharma Ltd Formulaciones y métodos para fabricar formulaciones para su uso en la evacuación colónica
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
BR112018016721A2 (pt) 2016-02-26 2018-12-26 Debiopharm Int Sa uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
CA3139942A1 (en) 2019-06-14 2020-12-17 Justyna NOWAKOWSKA Medicament and use thereof for treating bacterial infections involving biofilm
US11590154B2 (en) 2020-06-30 2023-02-28 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
ES2303351T3 (es) 2008-08-01
PT971735E (pt) 2008-06-02
EP0971735B1 (en) 2008-03-19
JP2008024713A (ja) 2008-02-07
EP0971735A4 (en) 2004-02-25
JP2012126736A (ja) 2012-07-05
IL132145A (en) 2005-11-20
NZ500696A (en) 2002-05-31
JP2001524951A (ja) 2001-12-04
CY1109783T1 (el) 2013-09-04
SI0971735T1 (sl) 2008-08-31
DE69839261D1 (de) 2008-04-30
DK0971735T3 (da) 2008-07-07
NO994778D0 (no) 1999-09-30
NO325947B1 (no) 2008-08-25
AR012304A1 (es) 2000-10-18
EP0971735A1 (en) 2000-01-19
US6277836B1 (en) 2001-08-21
CA2285923A1 (en) 1998-10-08
DE69839261T2 (de) 2009-03-26
WO1998043667A1 (en) 1998-10-08
IL132145A0 (en) 2001-03-19
CA2285923C (en) 2013-03-12
NO994778L (no) 1999-11-30

Similar Documents

Publication Publication Date Title
ATE389417T1 (de) Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69820997D1 (de) Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes
DE60003250D1 (de) Reinigungszusammensetzungen und Verfahren zur Reinigung
DE69834256D1 (de) Verfahren und zusammensetzung zur behandlung von verzögerten allergischen reaktionen und entzündungskrankheiten
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
EP1227821A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
ATE282591T1 (de) Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
DE69836200D1 (de) Implantat Material und Verfahren zu seiner Herstellung
DE60042184D1 (de) Verfahren und Zusammensetzung zur Entschichtung von Photoresist
EP1014995A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
DE60018635D1 (de) Monofilament und Verfahren zu seiner Herstellung
ATE288278T1 (de) Verfahren und zusammensetzungen zur peptidsynthese
DE69714828D1 (de) Verfahren zur Behandlung von Abfallstoffen
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
ATE271598T1 (de) Desinfektionszusammensetzungen und verfahren
ATE263777T1 (de) Zusammensetzungen zur behandlung von entzündungsreaktionen
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
DE69909355D1 (de) Verbundene Gegenstände und Verfahren zum Herstellen solcher verbundener Gegenstände
EP1109548A4 (en) Compositions and methods for treating and preventing bone diseases using tocotrienols
DE69732470D1 (de) Abbaubares Monofilament und Verfahren zu seiner Herstellung
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE69924489D1 (de) Getreide-beta-glukanzusammensetzungen und verfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0971735

Country of ref document: EP